COI Participated in ESMO TAT Asia Congress 2025

We’re delighted to share that our COO and Co-Directors recently attended the ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025, a premier event bringing together global leaders in early-phase oncology drug development.

Prof. Tak Mak, our esteemed Co-Director, delivered the unique Physician /Trialist Perspective on “Growing an ecosystem of biotech, pharma and drug developers in Asia”.

Prof. Aya El Helali, HKUMed Clinical Assistant Professor, one of our Centre’s collaborating Principal Investigators was also invited to speak, sharing critical insights on “Reporting exploratory biomarker analyses in early phase clinical trials: Pitfalls and precautions”—an important consideration in the era of precision oncology.

We were also honoured to see Prof. Lillian Siu from our international collaborating partner, University Health Network (UHN), delivering keynote address “Global development of phase I developmental therapeutics: An odyssey through recent decades”, highlighting the evolution and future of early-phase trials.

This gathering of minds underscores the importance of cross-border collaboration in accelerating cancer therapeutics. The connections made will continue to drive COI’s mission forward.

We thank the organizers and attendees for an inspiring conference and look forward to continuing our journey towards a brighter, more innovative future.

Stay updated on COI’s latest news and breakthroughs by following us on our social media platforms and visiting our website. Together, we can make a difference in the lives of those affected by cancer.